Cargando…

Adverse Reactions to Drugs of Special Interest in a Pediatric Oncohematology Service

Introduction: Drugs used in oncological diseases are frequently related to adverse drug reactions (ADR). Few studies have analyzed the toxicity of cancer treatments in children in real practice. Methods: An observational, longitudinal and prospective study has been carried out in an Oncohematology S...

Descripción completa

Detalles Bibliográficos
Autores principales: Amaro-Hosey, Kristopher, Danés, Immaculada, Vendrell, Lourdes, Alonso, Laura, Renedo, Berta, Gros, Luis, Vidal, Xavier, Cereza, Gloria, Agustí, Antònia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8131830/
https://www.ncbi.nlm.nih.gov/pubmed/34025429
http://dx.doi.org/10.3389/fphar.2021.670945
_version_ 1783694788544954368
author Amaro-Hosey, Kristopher
Danés, Immaculada
Vendrell, Lourdes
Alonso, Laura
Renedo, Berta
Gros, Luis
Vidal, Xavier
Cereza, Gloria
Agustí, Antònia
author_facet Amaro-Hosey, Kristopher
Danés, Immaculada
Vendrell, Lourdes
Alonso, Laura
Renedo, Berta
Gros, Luis
Vidal, Xavier
Cereza, Gloria
Agustí, Antònia
author_sort Amaro-Hosey, Kristopher
collection PubMed
description Introduction: Drugs used in oncological diseases are frequently related to adverse drug reactions (ADR). Few studies have analyzed the toxicity of cancer treatments in children in real practice. Methods: An observational, longitudinal and prospective study has been carried out in an Oncohematology Service of a tertiary hospital. During 2017, patients exposed to one or more drugs of a previously agreed list were identified and followed-up for at least 6 months each. Characteristics of ADR, incidence, causality and possible preventability, have been evaluated. Results: 72 patients have been treated with at least one study drug, and 159 ADR episodes involving at least one of these drugs have been identified, with a total of 293 ADR. Most episodes required hospital admission (35.2%) or happened during the hospital stay (33%), and 91.2% were severe. Blood disorders were the most frequent ADR (96; 32.8%), related to thioguanine (42) and pegaspargase (39) mainly, followed by infections (86; 29.4%) related to thioguanine (32), pegaspargase (27), Erwinia asparaginase (14) and rituximab (13). Two ADR were unknown. Most ADR were dose-dependent or expectable (>90%). The global incidence of ADR was 3.1/100 days at risk (95% CI 2.7–3.5), with 3.5 ADR/100 days at risk with pegaspargase (95% CI 2.9–4.2), 1.2/100 days at risk with rituximab (95% CI 0.8–1.8) and 11.6/100 days at risk with thioguanine (95% CI 9.4–14.2). Controversial additional measures of prevention, other than those already used, were identified. Conclusion: ADR are frequent in pediatric oncohematological patients, mainly blood disorders and infectious diseases. Findings regarding incidence and preventability may be useful to compare data between different centers and to evaluate new possibilities for action or prevention.
format Online
Article
Text
id pubmed-8131830
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-81318302021-05-20 Adverse Reactions to Drugs of Special Interest in a Pediatric Oncohematology Service Amaro-Hosey, Kristopher Danés, Immaculada Vendrell, Lourdes Alonso, Laura Renedo, Berta Gros, Luis Vidal, Xavier Cereza, Gloria Agustí, Antònia Front Pharmacol Pharmacology Introduction: Drugs used in oncological diseases are frequently related to adverse drug reactions (ADR). Few studies have analyzed the toxicity of cancer treatments in children in real practice. Methods: An observational, longitudinal and prospective study has been carried out in an Oncohematology Service of a tertiary hospital. During 2017, patients exposed to one or more drugs of a previously agreed list were identified and followed-up for at least 6 months each. Characteristics of ADR, incidence, causality and possible preventability, have been evaluated. Results: 72 patients have been treated with at least one study drug, and 159 ADR episodes involving at least one of these drugs have been identified, with a total of 293 ADR. Most episodes required hospital admission (35.2%) or happened during the hospital stay (33%), and 91.2% were severe. Blood disorders were the most frequent ADR (96; 32.8%), related to thioguanine (42) and pegaspargase (39) mainly, followed by infections (86; 29.4%) related to thioguanine (32), pegaspargase (27), Erwinia asparaginase (14) and rituximab (13). Two ADR were unknown. Most ADR were dose-dependent or expectable (>90%). The global incidence of ADR was 3.1/100 days at risk (95% CI 2.7–3.5), with 3.5 ADR/100 days at risk with pegaspargase (95% CI 2.9–4.2), 1.2/100 days at risk with rituximab (95% CI 0.8–1.8) and 11.6/100 days at risk with thioguanine (95% CI 9.4–14.2). Controversial additional measures of prevention, other than those already used, were identified. Conclusion: ADR are frequent in pediatric oncohematological patients, mainly blood disorders and infectious diseases. Findings regarding incidence and preventability may be useful to compare data between different centers and to evaluate new possibilities for action or prevention. Frontiers Media S.A. 2021-05-05 /pmc/articles/PMC8131830/ /pubmed/34025429 http://dx.doi.org/10.3389/fphar.2021.670945 Text en Copyright © 2021 Amaro-Hosey, Danés, Vendrell, Alonso, Renedo, Gros, Vidal, Cereza and Agustí. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Amaro-Hosey, Kristopher
Danés, Immaculada
Vendrell, Lourdes
Alonso, Laura
Renedo, Berta
Gros, Luis
Vidal, Xavier
Cereza, Gloria
Agustí, Antònia
Adverse Reactions to Drugs of Special Interest in a Pediatric Oncohematology Service
title Adverse Reactions to Drugs of Special Interest in a Pediatric Oncohematology Service
title_full Adverse Reactions to Drugs of Special Interest in a Pediatric Oncohematology Service
title_fullStr Adverse Reactions to Drugs of Special Interest in a Pediatric Oncohematology Service
title_full_unstemmed Adverse Reactions to Drugs of Special Interest in a Pediatric Oncohematology Service
title_short Adverse Reactions to Drugs of Special Interest in a Pediatric Oncohematology Service
title_sort adverse reactions to drugs of special interest in a pediatric oncohematology service
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8131830/
https://www.ncbi.nlm.nih.gov/pubmed/34025429
http://dx.doi.org/10.3389/fphar.2021.670945
work_keys_str_mv AT amarohoseykristopher adversereactionstodrugsofspecialinterestinapediatriconcohematologyservice
AT danesimmaculada adversereactionstodrugsofspecialinterestinapediatriconcohematologyservice
AT vendrelllourdes adversereactionstodrugsofspecialinterestinapediatriconcohematologyservice
AT alonsolaura adversereactionstodrugsofspecialinterestinapediatriconcohematologyservice
AT renedoberta adversereactionstodrugsofspecialinterestinapediatriconcohematologyservice
AT grosluis adversereactionstodrugsofspecialinterestinapediatriconcohematologyservice
AT vidalxavier adversereactionstodrugsofspecialinterestinapediatriconcohematologyservice
AT cerezagloria adversereactionstodrugsofspecialinterestinapediatriconcohematologyservice
AT agustiantonia adversereactionstodrugsofspecialinterestinapediatriconcohematologyservice